FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease

Table 3

Means and standard deviations of the percentage of methylation detected at each CpG site in KD patients responding or not responding to intravenous immunoglobulin treatment.

Gene	CpG sites	Methylation (%)						value
		IVIG-nonresponsive patients ()			IVIG-responsive patients ()
		Mean	SD	95% CI	Mean	SD	95% CI
FCGR2A	A	80.06	4.51	77.33–82.79	80.94	5.55	78.48–83.40	0.6319
	B	71.40	6.65	67.39–75.42	57.55	7.11	54.40–60.70	<0.0001^***
	C	72.93	5.64	69.52–76.34	68.40	5.09	66.15–70.66	0.0201^*
	D	69.46	4.72	66.60–72.31	66.85	5.28	64.50–69.19	0.1516
	E	67.65	4.43	64.97–70.33	57.90	3.03	56.56–59.25	<0.0001^***
	F	88.34	4.92	85.37–91.31	78.47	5.98	75.82–81.12	<0.0001^***
	G	68.38	5.71	64.93–71.83	68.95	5.48	66.52–71.38	0.7723
	H	55.32	9.42	49.63–61.02	36.38	6.33	33.57–39.19	<0.0001^***
	I	83.56	5.59	80.18–86.94	83.48	5.83	80.89–86.06	0.9650
	J	69.26	6.72	65.19–73.32	58.53	6.22	55.77–61.29	<0.0001^***
	K	71.30	6.92	67.12–75.48	65.27	6.68	62.31–68.24	0.0158^*

The statistical significance , .